Abridge was last valued at $5.3B (post-money). It comes from the $316M Series E extension of Apr 2026. The company is private, so there is no listed share price.
2 valuations. The latest, $5.3B post-money, was set by the Series E extension in Apr 2026.
A private valuation is the price agreed in one transaction. The Abridge valuation of $5.3B is a post-money figure from the Series E extension dated 1 Apr 2026 — the whole company measured after the $316M raised in that round was already inside it. Subtract the round and the pre-money view of the same deal is $5B .
The valuation holds until the next priced round or secondary sale. A private company founded in 2018 with roughly 200 people has no daily price and no order book between rounds.
The closest healthcare technology and ai (ai-powered clinical documentation) peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Abridge is a private company; its shares do not trade on a public exchange.
The last valuation is $5.3B (post-money, Apr 2026).
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
